Sarah Greene

Immunology and Microbiology · Life Sciences

5h-index646citations33works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(26), Cancer Immunotherapy and Biomarkers(15), Immune cells in cancer(9), CAR-T cell therapy research(9), Chemokine receptors and signaling(7)

Publications33 total

Supplementary Data from Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
2023Open Access
Supplementary Figure S7 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Supplementary Figure S4 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Supplementary Figure S2 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Supplementary Methods from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Supplementary Figure S8 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Supplementary Figure S5 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Supplementary Figure S6 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Supplementary Data from Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
2023Open Access
Data from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Supplementary Figure S1 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Data from Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
2023Open Access
Supplementary Figure S6 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Supplementary Figure S5 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Supplementary Figure S3 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Data from Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
2023Open Access
Supplementary Figure S7 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Supplementary Figure S3 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Supplementary Figure S1 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
Supplementary Figure S2 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Clint Allen(32), Yvette Robbins(31), Paúl E. Clavijo(31), Jay Friedman(30), Wojciech K. Mydlarz(26), Nicole C. Schmitt(26), Jeffrey Schlom(26), Claudia Palena(23), Dean Y. Maeda(23), John A. Zebala(23), Lucas A. Horn(22), Angel P. Huynh(21), James W. Hodge(8), Lillian Sun(6), Carter Van Waes(5), Ellen Moore(5), Paul Zolkind(5), Megan V. Morisada(5), Hans Schreiber(5), Ravindra Uppaluri(5)